Apriset Cap Kit 125 is a specialized antiemetic kit comprising Aprepitant capsules designed specifically for adults and pediatric patients undergoing highly or moderately emetogenic chemotherapy. This kit includes a 125 mg capsule for Day 1 and two 80 mg capsules for Days 2 and 3, offering a comprehensive 3-day oral regimen. Aprepitant is a potent neurokinin-1 (NK1) receptor antagonist that effectively blocks substance P, a key neurotransmitter responsible for chemotherapy-induced nausea and vomiting (CINV). When used as part of a triple antiemetic regimen alongside 5-HT3 receptor antagonists and corticosteroids, Apriset Cap Kit 125 enhances patient comfort, reduces emesis, and minimizes treatment interruptions. It is manufactured for oncology supportive care and is essential for improving chemotherapy tolerance and adherence. The product requires strict oncologist supervision, proper storage below 30°C away from moisture and light, and careful consideration of drug interactions with medications such as warfarin and oral contraceptives.
Key Features
| Features | Description |
|---|---|
| Composition | 1 x 125 mg Aprepitant capsule (Day 1) + 2 x 80 mg Aprepitant capsules (Days 2 & 3) |
| Active Ingredient | Aprepitant (Neurokinin-1 receptor antagonist) |
| Therapeutic Use | Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) |
| Dosage Regimen | 125 mg orally 1 hour before chemotherapy on Day 1; 80 mg orally on Days 2 and 3 |
| Formulation | Oral capsules in a blister pack |
| Indications | Used in highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) protocols |
| Packaging | 1 blister pack containing 3 capsules for a complete 3-day course |
| Storage Conditions | Store below 30°C, protect from light and moisture |
| Compatibility | Used with 5-HT3 receptor antagonists and corticosteroids for optimal antiemetic effect |
| Safety | Requires oncologist supervision; not recommended during pregnancy or breastfeeding unless necessary |
| Attributes | Description |
|---|---|
| Manufacturer | Various Indian brands, commonly marketed as Apriset |
| Generic Name | Aprepitant |
| Kit Composition | 1 capsule of 125 mg and 2 capsules of 80 mg Aprepitant |
| Therapeutic Category | Oncology Supportive Care > Antiemetic |
| Mechanism of Action | Blocks substance P at NK1 receptors to prevent both acute and delayed CINV |
| Route of Administration | Oral |
| Storage | Below 30°C, dry place, protect from light and moisture |
| Drug Interactions | May interact with warfarin, dexamethasone, oral contraceptives; dose adjustments may be required |
| Age Group | Adults and pediatric patients |
| Regulatory Status | Prescription only, under oncologist supervision |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
No, Apriset Cap Kit 125 is intended to be used as part of a triple antiemetic regimen, typically with a 5-HT3 receptor antagonist and a corticosteroid, for optimal prevention of CINV.
Store the kit below 30°C in a dry place, protecting it from light and moisture to maintain stability and effectiveness.
Yes, patients taking warfarin or oral contraceptives may require dose adjustments as Aprepitant can influence their metabolism; oncologist supervision is essential.
One 125 mg capsule is taken orally approximately 1 hour before chemotherapy on Day 1, followed by one 80 mg capsule each morning on Days 2 and 3.
Yes, Apriset Cap Kit 125 is indicated for both adult and pediatric patients, though dosing and administration should be strictly managed by an oncologist.
Country Of Origin: India
Product Name: Apriset Cap Kit 125
Generic Name (Kit composition):
• Aprepitant 125 mg capsule (Day 1)
• Aprepitant 80 mg capsules (Day 2 & Day 3)
Manufacturer:
Commonly marketed in India (brands vary; “Apriset” is a known oncology supportive care brand).
Therapeutic Category:
Oncology Supportive Care / Antiemetic
Product Description:
Apriset Cap Kit 125 contains Aprepitant, a neurokinin-1 (NK1) receptor antagonist, used for the prevention of nausea and vomiting associated with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).
It is usually given as part of a triple antiemetic regimen with a 5-HT3 receptor antagonist (e.g., ondansetron) and a corticosteroid (e.g., dexamethasone).
Indications:
• Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adult and pediatric patients.
Mechanism of Action:
• Aprepitant blocks the action of substance P at NK1 receptors in the brain.
• This prevents both acute (within 24 hrs) and delayed (after 24 hrs) chemotherapy-induced vomiting.
Dosage & Administration (Typical Kit Use):
• Day 1 (prior to chemotherapy): 125 mg orally, 1 hour before chemotherapy.
• Day 2 & 3: 80 mg orally, once daily in the morning.
• Must be taken with other prescribed antiemetics for best results.
Key Benefits:
• Provides strong protection against chemotherapy-related nausea and vomiting.
• Convenient 3-day oral kit improves compliance.
• Reduces risk of treatment interruptions due to emesis.
Packaging:
• Apriset Cap Kit 125: 1 blister pack containing
o 1 x 125 mg capsule (Day 1)
o 2 x 80 mg capsules (Day 2 & 3)
Storage:
• Store below 30°C, in a dry place.
• Protect from light and moisture.
Important Notes:
• To be used only under oncologist’s supervision.
• Not recommended during pregnancy or breastfeeding unless necessary.
• May interact with warfarin, dexamethasone, and oral contraceptives (dose adjustments may be required).
EXPORTERS OF ONCOLOGY PRODUCTS FROM INDIA
Melizza Lifescience
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
